Status:

COMPLETED

Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis

Lead Sponsor:

Landos Biopharma Inc.

Conditions:

Ulcerative Colitis

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

Brief Summary

This is a Phase 1b, randomized, double-blind, multicenter dose-ranging study to evaluate the safety, tolerability, and PK of NX-13. Approximately 40 subjects will be randomized in a 3:3:3:1 ratio to r...

Detailed Description

Following screening period (up to 28 days in length), a total of 40 subjects are planned to be enrolled into this study from multiple sites in the United States, Australia, New Zealand, and Moldova. E...

Eligibility Criteria

Inclusion

  • Key
  • male and female subjects aged 18 to 75 years (inclusive) with a diagnosis of UC ≥ 90 days before screening;
  • active UC defined as a total Mayo Score of 4 to 10 (inclusive), at baseline, with a Mayo endoscopic subscore (MES) ≥ 2 confirmed by a central reader;
  • baseline fecal calprotectin ≥ 250 μg/g;
  • biologic-naïve or having stopped biologic therapy ≥ 8 weeks before the start of the study;
  • 5-aminosalicylates must be stable for ≥ 1 month prior to randomization.
  • Key

Exclusion

  • Crohn's disease (CD), indeterminate colitis, or presence or history of fistula with CD;
  • a history of toxic megacolon, abdominal abscess, symptomatic colonic stricture, or stoma;
  • history of or at imminent risk of colectomy;
  • history of or current colonic dysplasia ;
  • recent history (within 2 years prior to randomization) or current adenomatous colonic polyps;
  • treatment with an immunosuppressant within 3 months of randomization;
  • bacterial or parasitic pathogenic enteric infection;
  • live virus vaccination within 1 month prior to screening.

Key Trial Info

Start Date :

May 5 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 5 2022

Estimated Enrollment :

39 Patients enrolled

Trial Details

Trial ID

NCT04862741

Start Date

May 5 2021

End Date

October 5 2022

Last Update

February 15 2023

Active Locations (31)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 8 (31 locations)

1

Avant Research Associates LLC

Huntsville, Alabama, United States, 35802

2

Om Research LLC

Lancaster, California, United States, 93534

3

Allameh Medical Corporation

Mission Viejo, California, United States, 92691

4

California Medical Research Associates, Inc.

Northridge, California, United States, 91324

Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis | DecenTrialz